	US 11,725,050 B2
	Anti-interleukin-33 antibodies and uses thereof
Philip E. Hass, Moss Beach, CA (US); Meredith Hazen, Belmont, CA (US); Yi-Chun Hsiao, San Mateo, CA (US); Rajita Khosla, Foster City, CA (US); Gerald R. Nakamura, San Francisco, CA (US); Dhaya Seshasayee, Cupertino, CA (US); Menno Van Lookeren Campagne, San Francisco, CA (US); Hongkang Xi, South San Francisco, CA (US); Wenwu Zhai, Redwood City, CA (US); Jack Bevers, III, San Francisco, CA (US); and Nancy Chiang, San Francisco, CA (US)
Assigned to Genentech, Inc., South San Francisco, CA (US)
Filed by Genentech, Inc., South San Francisco, CA (US)
Filed on Jun. 16, 2020, as Appl. No. 16/903,300.
Application 16/903,300 is a division of application No. 16/119,667, filed on Aug. 31, 2018, granted, now 10,723,795.
Application 16/119,667 is a division of application No. 14/937,778, filed on Nov. 10, 2015, granted, now 10,093,730, issued on Oct. 9, 2018.
Claims priority of provisional application 62/165,732, filed on May 22, 2015.
Claims priority of provisional application 62/077,876, filed on Nov. 10, 2014.
Prior Publication US 2021/0002361 A1, Jan. 7, 2021
Int. Cl. C07K 16/24 (2006.01); A61K 39/395 (2006.01); C12N 15/63 (2006.01); C07K 16/22 (2006.01); C07K 16/40 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/244 (2013.01) [A61K 39/3955 (2013.01); C07K 16/22 (2013.01); C07K 16/40 (2013.01); C12N 15/63 (2013.01); A61K 2039/507 (2013.01); C07K 2317/14 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/41 (2013.01); C07K 2317/53 (2013.01); C07K 2317/54 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

28 Claims

1. A method of treating age-related macular degeneration (AMD) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an antibody that specifically binds IL-33, wherein the antibody comprises a binding domain comprising the following six hypervariable regions (HVRs):

(a) an HVR-H1 comprising the amino acid sequence of SFSX₁S (SEQ ID NO: 62), wherein X, is Met, Leu, or Val;

(b) an HVR-H2 comprising the amino acid sequence of TISGGKTFTDYVDX₁VKG (SEQ ID NO: 63), wherein X₁is Ser or Ala;

(c) an HVR-H3 comprising the amino acid sequence of ANYGX₁X₂FFEV (SEQ ID NO: 64), wherein X₁is Asn or Asp, and X2 is Trp or Phe;

(d) an HVR-L1 comprising the amino acid sequence of RASESVAKYGLSLLN (SEQ ID NO: 4);

(e) an HVR-L2 comprising the amino acid sequence of AASNRGS (SEQ ID NO: 5); and

(f) an HVR-L3 comprising the amino acid sequence of QQSKEVPFT (SEQ ID NO: 6).